About
Allan-Herndon Dudley Syndrome (AHDS)
AHDS is a devastating condition affecting children and results in significant healthcare needs and lifelong dependency
What is MCT-8 Deficiency?
MCT-8 deficiency (Monocarboxylate Transporter 8 deficiency), also known as Allan-Herndon-Dudley Syndrome (AHDS), is a rare genetic disorder that affects thyroid hormone transport and neurodevelopment. Although rare, this condition has a significant impact on affected individuals and their families. This blog aims to provide a comprehensive overview of MCT-8 deficiency, its causes, symptoms, diagnosis, and potential treatment options.
MCT-8 deficiency is caused by mutations in the SLC16A2 gene, which encodes the Monocarboxylate Transporter 8 (MCT-8) protein. This protein is responsible for transporting thyroid hormones – primarily triiodothyronine (T3) into cells. When MCT-8 is defective or absent, thyroid hormones cannot effectively reach certain tissues, especially the brain, leading to developmental delays and other symptoms.
Key Symptoms
The symptoms of MCT-8 deficiency vary but generally include the following:
​
-
Severe Developmental Delays: Children with MCT-8 deficiency often experience delayed milestones such as sitting, standing, and walking. Speech development is typically impaired or absent.
​
-
Hypotonia: Low muscle tone is common, leading to muscle weakness and difficulty with movement.
​
-
Spasticity: Some individuals experience increased muscle stiffness or involuntary muscle movements.
​
-
Intellectual Disability: Cognitive impairment is a hallmark of the condition.
​
-
Abnormal Thyroid Function Tests: Laboratory tests often reveal elevated T3 levels and low reverse T3 (rT3) levels.
Diagnosis
Diagnosing MCT-8 deficiency typically involves a combination of:
​
-
Clinical Evaluation: A thorough assessment of developmental delays, muscle tone, and thyroid-related symptoms.
​
-
Thyroid Function Tests: Elevated serum T3 levels are often a red flag for MCT-8 deficiency.
​​
-
Genetic Testing: A definitive diagnosis is made by identifying mutations in the SLC16A2 gene through genetic sequencing.
Treatment
There is currently no cure for MCT-8 deficiency, but several approaches aim to manage symptoms and improve quality of life:
​
-
Symptom Management: Physical therapy, occupational therapy, and speech therapy can help maximize developmental potential.
-
Hormone Modulation: Research is ongoing into therapies that can modify thyroid hormone levels or mimic MCT-8’s function to improve brain hormone transport.
-
Nutritional Support: Ensuring proper nutrition is critical for overall health and development.
-
Clinical Trials: Some patients may qualify for experimental treatments or clinical trials aimed at improving outcomes.
